<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986752</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. B00101</org_study_id>
    <nct_id>NCT00986752</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease</brief_title>
  <acronym>ISAR-STATH</acronym>
  <official_title>Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of stenting after dilation with or
      without paclitaxel-eluting balloon or atherectomy in patients with symptomatic peripheral
      artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The superficial femoral artery is a common place for arteriosclerosis in patients symptomatic
      for lower extremity vascular disease. Advances in percutaneous transluminal angioplasty (PTA)
      and stenting have provided new options for the treatment of the disease in this arterial
      segment. Despite the initial technical success rate of more than 95% the late clinical
      failure remains an important concern.

      Restenosis after PTA occurs in 40-60% within one year. Percutaneous removal of the
      obstructive material through atherectomy may reduce restenosis rate. So far, data in support
      of excisional atherectomy derive from registries. Another attempt to reduce restenosis is the
      use of paclitaxel eluting balloons (PEB). First clinical studies suggest that the use of PEBs
      during percutaneous treatment of femoropopliteal disease is associated with significant
      reductions in late lumen loss and target-lesion revascularization.

      There is no randomized comparison of this three different interventional strategies. Thus the
      aim of this study is to evaluate the efficacy of these strategies in terms or reduction of
      diameter stenosis at follow-up angiogram.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage diameter stenosis</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse peripheral events (MAPE) defined as acute thrombosis of SFA or ipsilateral amputation or revascularization (PTA or bypass surgery)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of any of MAPE.</measure>
    <time_frame>3-24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage diameter stenosis in duplex ultrasound</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in functional status and health related quality of life (Walking Impairment Questionaire)</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Stenting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Due to randomization one nitinol stent will be implanted after dilation with a conventional balloon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stenting after PEB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Due to randomization one nitinol stent will be implanted after dilation with a Paclitaxel eluting balloon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atherectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The third randomization arm is Atherectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stenting (Smart Stent)</intervention_name>
    <description>Nitinol stent</description>
    <arm_group_label>Stenting</arm_group_label>
    <arm_group_label>Stenting after PEB</arm_group_label>
    <other_name>Smart Stent, Cordis, Johnson &amp; Johnson</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stenting after PEB (Smart Stent, Invatec)</intervention_name>
    <description>Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).</description>
    <arm_group_label>Stenting after PEB</arm_group_label>
    <other_name>Invatec</other_name>
    <other_name>Smart Stent, Cordis, Johnson &amp; Johnson</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atherectomy (SilverHawk device)</intervention_name>
    <description>Atherectomy</description>
    <arm_group_label>Atherectomy</arm_group_label>
    <other_name>SilverHawk device (EV3 Inc)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic ≥ 70% stenosis of the SFA (Rutherford stage 2-6)

          -  Written informed consent

        Exclusion Criteria:

          -  Acute ischemia and/or acute thrombosis of the SFA

          -  Untreated ipsilateral iliac artery stenosis &gt;70%

          -  Previous stenting of the SFA

          -  Popliteal stenosis &gt;70%

          -  Severe renal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilka Ott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum rechts der Isar</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klaus Tiroch, MD</last_name>
    <phone>+49-89-1218</phone>
    <phone_ext>1538</phone_ext>
    <email>tiroch@dhm.mhn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tarek Ibrahim, MD</last_name>
    <phone>+49 89-1218</phone>
    <phone_ext>4018</phone_ext>
    <email>ibrahim@dhm.mhn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deutsches Herzzentrum</name>
      <address>
        <city>Muenchen</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimiliano Fusaro, MD</last_name>
      <phone>+49 89-1218</phone>
      <phone_ext>4566</phone_ext>
      <email>fusaro@dhm.mhn.de</email>
    </contact>
    <contact_backup>
      <last_name>Tarek Ibrahim, MD</last_name>
      <phone>+49 89-1218</phone>
      <phone_ext>4016</phone_ext>
      <email>ibrahim@dhm.mhn.de</email>
    </contact_backup>
    <investigator>
      <last_name>Massimiliano Fusaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I. Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilka Ott, MD</last_name>
      <phone>+49-89-4140</phone>
      <phone_ext>4360</phone_ext>
      <email>ott@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Ilka Ott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>March 6, 2014</last_update_submitted>
  <last_update_submitted_qc>March 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stent</keyword>
  <keyword>atherectomy</keyword>
  <keyword>paclitaxel-eluting balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

